Evaluating pertussis vaccine effectiveness in children under 5 years of age born in France between 2013 and 2019

Juan C Vargas-Zambrano1, Mickael Arnaud2, Ana Antunes3

  • 1Global Medical, Vaccines, Sanofi, Lyon, France.

Vaccine
|March 25, 2026
PubMed

Insights

France

Area of Science:

  • Public Health
  • Epidemiology
  • Vaccinology

Background:

  • Pertussis (whooping cough) remains a global health concern despite available vaccines.
  • France updated its pediatric pertussis vaccination schedule in 2013 from a 3+1 to a 2+1 regimen.
  • Limited data existed on pediatric pertussis vaccine effectiveness in France post-2013 schedule change.

Purpose of the Study:

  • To assess the effectiveness of the pertussis vaccine in French children born between 2013 and 2019.
  • To evaluate the impact of the revised 2+1 vaccination schedule on pertussis protection.
  • To quantify vaccine effectiveness (VE) based on the number of vaccine doses received.

Main Methods:

  • A matched case-control study utilizing the French National Health Data System.
  • Inclusion criteria: children alive and pertussis-free at 6 weeks with mother-child linkage.
  • Pertussis cases identified via ICD-10 codes; vaccine exposure confirmed by ATCC codes. Conditional logistic regression used to calculate odds ratios (ORs) and estimate VE.

Main Results:

  • Analysis included 1,481,884 children, revealing a dose-dependent increase in vaccine effectiveness.
  • Highest VE (93.4%) observed in fully vaccinated children (2+1 schedule) aged 11.5-60 months.
  • Lowest VE (24.1%) observed in infants aged 2-4.5 months receiving only the first dose. Sensitivity analyses indicated a ~6% VE increase with imputed data.

Conclusions:

  • Adherence to the 2+1 pertussis vaccination schedule provides significant protection against the disease in full-term infants in France.
  • The study confirms the effectiveness of the current pediatric vaccination strategy in France.
  • Findings support the continued use and monitoring of the 2+1 schedule for pertussis prevention.

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...